Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 12, 2025
Ultragenyx anuncia la aprobación de Evkeeza® (evinacumab) por parte de la COFEPRIS para el tratamiento de la Hipercolesterolemia Familiar Homocigota (HoFH)
GlobeNewswire
·
March 12, 2025
CIUDAD DE MÉXICO, March 12, 2025 (GLOBE NEWSWIRE) -- Ultragenyx México S. de R. L. de C. V., una empresa biofarmacéutica enfocada en el desarrollo y comercialización de terapias innovadoras para enfermedades genéticas raras y ultra raras, anuncia la …
American Kidney Fund's 5th Annual Living Donor Report Card Reveals Mixed Progress, Calls for Urgent Action to Support Living Donors
GlobeNewswire
·
March 12, 2025
ROCKVILLE, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) released its fifth annual State of the States: Living Donor Protection Report Card with updates revealing an urgent need for stronger living organ donor legal …
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
GlobeNewswire
·
March 12, 2025
New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage …
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
GlobeNewswire
·
March 12, 2025
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated …
Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 12, 2025
Net sales for the year ended December 31, 2024 were $57.8 million, down 5.5% compared to $61.2 million for the year ended December 31, 2023 Net income for the year ended December 31, 2024 was $3.9 million, or $0.35 per diluted share, compared to $4.2 …
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
GlobeNewswire
·
March 12, 2025
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and …
Cylinder joins Teladoc Health’s Connected Care Program to expand access to virtual digestive care
GlobeNewswire
·
March 12, 2025
CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) -- Cylinder, the leading virtual digestive health provider, today announced its partnership with Teladoc Health (NYSE: TDOC), the global leader in virtual care, to expand access to high-quality, personalized …
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
GlobeNewswire
·
March 12, 2025
ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
GlobeNewswire
·
March 12, 2025
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)- …
Pattern Unveils Adaptive Example Selection™ (AES™) Framework to Revolutionize Medical AI Interpretability
GlobeNewswire
·
March 12, 2025
REDMOND, Wash., March 12, 2025 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”), a leader in cutting-edge explainable AI (XAI) research, has introduced a transformative new framework, Adaptive Example Selection™ (AES™), designed to …
Iolyx Therapeutics to Present at Multiple Upcoming Ophthalmology Conferences
GlobeNewswire
·
March 12, 2025
BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Iolyx Therapeutics, a clinical-stage biotechnology company focused on the development of therapeutics at the intersection of ocular inflammation and autoimmunity, today announced acceptance of …
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing
GlobeNewswire
·
March 12, 2025
VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced …
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
GlobeNewswire
·
March 12, 2025
ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, …
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
GlobeNewswire
·
March 12, 2025
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio …
Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management
GlobeNewswire
·
March 12, 2025
Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. ( …
FOXO TECHNOLOGIES INC. PROVIDES UPDATE ON ITS BEHAVIORAL HEALTH SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC.
GlobeNewswire
·
March 12, 2025
MINNEAPOLIS, MN, March 12, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company or FOXO”), provides an update on Myrtle Recovery Centers, Inc., (“Myrtle”) and its behavioral health facility in Oneida, Tennessee, and confirms …
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
GlobeNewswire
·
March 12, 2025
DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in …
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
GlobeNewswire
·
March 12, 2025
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one …
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
GlobeNewswire
·
March 12, 2025
NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s …
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
GlobeNewswire
·
March 12, 2025
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including …